Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $138.0 million.

  • Phathom Pharmaceuticals' Cash & Equivalents fell 5911.06% to $138.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.0 million, marking a year-over-year decrease of 5911.06%. This contributed to the annual value of $300.1 million for FY2024, which is 2189.45% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Cash & Equivalents stood at $138.0 million for Q3 2025, which was down 5911.06% from $152.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Cash & Equivalents ranged from a high of $384.3 million in Q4 2023 and a low of $130.1 million during Q1 2023
  • For the 4-year period, Phathom Pharmaceuticals' Cash & Equivalents averaged around $228.5 million, with its median value being $215.2 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 14992.2% in 2024, then plummeted by 5911.06% in 2025.
  • Phathom Pharmaceuticals' Cash & Equivalents (Quarter) stood at $155.9 million in 2022, then skyrocketed by 146.49% to $384.3 million in 2023, then fell by 21.89% to $300.1 million in 2024, then plummeted by 54.01% to $138.0 million in 2025.
  • Its Cash & Equivalents was $138.0 million in Q3 2025, compared to $152.4 million in Q2 2025 and $215.2 million in Q1 2025.